Human natural antibodies and complement components recognizing porcine glycan antigens (XNA-C)

Human natural antibodies and complement components recognizing porcine glycan antigens refers to the primary immunological barrier in xenotransplantation, where pre-existing human antibodies (mostly IgM) bind to carbohydrate structures on porcine cells [Cooper et al., 2023]. The most significant of these antigens is Galactose-alpha-1,3-galactose (alpha-Gal), which is absent in humans but ubiquitously expressed in pigs [Niu et al., 2021]. Upon binding, these antibodies activate the classical complement pathway, leading to the formation of the membrane attack complex and subsequent hyperacute rejection of the porcine graft [Mohiuddin et al., 2022]. This process causes rapid endothelial damage, thrombosis, and organ failure within minutes to hours. Therapeutic strategies to overcome this barrier include the use of genetically engineered pigs (e.g., alpha-Gal knockout), antibody depletion techniques, and complement-inhibiting drugs like eculizumab or pegcetacoplan [Griffith et al., 2022]. Understanding and modulating this interaction is critical for the clinical viability of pig-to-human organ transplantation.

Other names

Xenoreactive natural antibodies (XNAs)Anti-alpha-Gal antibodiesAnti-pig antibodiesXenoantigen-antibody-complement axisPorcine-reactive complement system

Inhibition of the complement cascade (e.g., C3 or C5 inhibition) to prevent membrane attack complex formation, enzymatic cleavage of xenoreactive IgG antibodies, or competitive neutralization of natural antibodies using soluble glycan mimetics [Cooper et al., 2023; Katopodis et al., 2002].